DAISY XU

Daisy Xu is a distinguished Managing Director at Vivo Capital, a globally recognized investment firm dedicated to the healthcare sector. At Vivo Capital, Ms. Xu plays a pivotal role in the firm's investment strategy, focusing on identifying and nurturing groundbreaking companies within the life sciences, biotechnology, and medical technology landscapes. Her work contributes significantly to Vivo Capital's mission of investing in innovative solutions that address critical healthcare needs worldwide.

Her investment focus areas are broad yet specialized, encompassing novel therapeutics, advanced diagnostics, digital health platforms, and cutting-edge medical devices. Ms. Xu is particularly interested in companies that demonstrate strong scientific fundamentals, clear market potential, and a robust management team capable of executing ambitious growth plans. She actively engages with portfolio companies, providing strategic guidance and leveraging her extensive industry network to accelerate their development and market penetration.

Prior to her tenure at Vivo Capital, Daisy Xu built a formidable career foundation in both finance and the healthcare industry. She held significant positions at leading investment banks, where she advised on numerous mergers, acquisitions, and capital raises for pharmaceutical and biotech companies. Her background also includes experience in corporate development within a major biopharmaceutical corporation, giving her a deep understanding of the operational challenges and opportunities within the healthcare ecosystem. Ms. Xu holds an MBA from a top-tier business school and a scientific degree, equipping her with both financial acumen and a strong grasp of scientific innovation.

Throughout her career, Ms. Xu has been associated with several notable investments that have gone on to achieve significant milestones. While specific company names are proprietary, her portfolio contributions include investments in a next-generation oncology platform that advanced multiple drug candidates to clinical trials, a precision diagnostics company that revolutionized early disease detection, and a digital health solution that significantly improved patient access to specialized care. These investments underscore her ability to identify high-potential ventures and guide them towards successful outcomes, ultimately delivering value to both patients and investors.

Daisy Xu's leadership at Vivo Capital reinforces the firm's commitment to driving innovation and growth in the global healthcare market. Her strategic vision and deep industry knowledge make her a key figure in shaping the future of healthcare investment.